Page last updated: 2024-08-24

naphthalimides and Leukemia

naphthalimides has been researched along with Leukemia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I1
Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S1

Trials

1 trial(s) available for naphthalimides and Leukemia

ArticleYear
Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
    Cancer research, 1991, Feb-01, Volume: 51, Issue:3

    Topics: Acute Disease; Adenine; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imides; Isoquinolines; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Precursor Cell Lymphoblastic Leukemia-Lymphoma

1991

Other Studies

1 other study(ies) available for naphthalimides and Leukemia

ArticleYear
Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.
    European journal of medical research, 2003, Oct-22, Volume: 8, Issue:10

    Topics: 1-Naphthylamine; Adenosine Triphosphate; Alkylating Agents; Apoptosis; Benzamides; Cell Death; Cell Line, Tumor; Cell Size; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Melphalan; Methylnitronitrosoguanidine; NAD; Naphthalimides; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones

2003